Product Name
DNAI1, siRNA
Full Product Name
DNAI1 siRNA (Mouse)
Product Synonym Names
DNAIC1; Dynein intermediate chain 1. axonemal; Axonemal dynein intermediate chain 1
Product Gene Name
DNAI1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q8C0M8
Specificity
DNAI1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse DNAI1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of DNAI1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
DNAI1 sirna
siRNA to inhibit DNAI1 expression using RNA interference
Applications Tested/Suitable for DNAI1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for DNAI1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_780347.2
[Other Products]
NCBI GenBank Nucleotide #
NM_175138.4
[Other Products]
UniProt Primary Accession #
Q8C0M8
[Other Products]
UniProt Secondary Accession #
Q8BKY5[Other Products]
UniProt Related Accession #
Q8C0M8[Other Products]
Molecular Weight
79,758 Da
NCBI Official Full Name
dynein intermediate chain 1, axonemal
NCBI Official Synonym Full Names
dynein, axonemal, intermediate chain 1
NCBI Official Symbol
Dnaic1??[Similar Products]
NCBI Official Synonym Symbols
Dnai1; BB124644; b2b1526Clo; 1110066F04Rik
??[Similar Products]
NCBI Protein Information
dynein intermediate chain 1, axonemal
UniProt Protein Name
Dynein intermediate chain 1, axonemal
UniProt Synonym Protein Names
Axonemal dynein intermediate chain 1
UniProt Gene Name
Dnai1??[Similar Products]
UniProt Synonym Gene Names
Dnaic1??[Similar Products]
UniProt Entry Name
DNAI1_MOUSE
UniProt Comments for DNAI1
DNAI1: Part of the dynein complex of respiratory cilia. Defects in DNAI1 are the cause of primary ciliary dyskinesia type 1 (CILD1). CILD1 is an autosomal recessive disorder characterized by axonemal abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia; reduced fertility is often observed in male patients due to abnormalities of sperm tails. Half of the patients exhibit situs inversus, due to dysfunction of monocilia at the embryonic node and randomization of left-right body asymmetry. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. Defects in DNAI1 are the cause of Kartagener syndrome (KTGS). KTGS is an autosomal recessive disorder characterized by the association of primary ciliary dyskinesia with situs inversus. Clinical features include recurrent respiratory infections, bronchiectasis, infertility, and lateral transposition of the viscera of the thorax and abdomen. The situs inversus is most often total, although it can be partial in some cases (isolated dextrocardia or isolated transposition of abdominal viscera). Belongs to the dynein intermediate chain family.
Protein type: Motility/polarity/chemotaxis; Cytoskeletal
Cellular Component: dynein complex; microtubule; cell projection; cytoskeleton; cytoplasm; cilium
Molecular Function: motor activity
Research Articles on DNAI1
1. Motile nodal cilia patterns heart looping but heart and visceral organ lateralization is driven by signaling not requiring nodal cilia motility. Dnaic1 mutants can achieve situs solitus or inversus even with immotile nodal cilia.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
